These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 29993139)

  • 21. Expression of PTEN, Androgen Receptor, HER2/neu, Cytokeratin 5/6, Estrogen Receptor-Beta, HMGA2, and PLAG1 in Salivary Duct Carcinoma.
    Liang L; Williams MD; Bell D
    Head Neck Pathol; 2019 Dec; 13(4):529-534. PubMed ID: 30390196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Salivary duct carcinoma: the predominance of apocrine morphology, prevalence of histologic variants, and androgen receptor expression.
    Williams L; Thompson LD; Seethala RR; Weinreb I; Assaad AM; Tuluc M; Ud Din N; Purgina B; Lai C; Griffith CC; Chiosea SI
    Am J Surg Pathol; 2015 May; 39(5):705-13. PubMed ID: 25871467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Survival analysis and immunohistochemical study of HER-2 and AR (androgen receptor) expression in salivary duct carcinoma].
    Otsuka K; Imanishi Y; Habu N; Sato Y; Shigetomi S; Fujii R; Sakamoto K; Tomita T; Fujii M; Kameyama K; Ogawa K
    Nihon Jibiinkoka Gakkai Kaiho; 2013 Sep; 116(9):1024-32. PubMed ID: 24191589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry.
    Udager AM; Chiosea SI
    Head Neck Pathol; 2017 Sep; 11(3):288-294. PubMed ID: 28321773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genomic alteration in rare subtype of sarcomatoid salivary duct carcinoma.
    Jeong JS; Cho KJ; Kim D; Lee YS; Song JS
    Pathol Res Pract; 2021 Dec; 228():153678. PubMed ID: 34781210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased expression of USP22 is associated with disease progression and patient prognosis of salivary duct carcinoma.
    Piao S; Ma J; Wang W; Liu Y; Zhang M; Chen H; Guo F; Zhang B; Guo F
    Oral Oncol; 2013 Aug; 49(8):796-801. PubMed ID: 23664741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands.
    Boon E; Bel M; van Boxtel W; van der Graaf WTA; van Es RJJ; Eerenstein SEJ; Baatenburg de Jong RJ; van den Brekel MWM; van der Velden LA; Witjes MJH; Hoeben A; Willems SM; Bloemena E; Smit LA; Oosting SF; ; Jonker MA; Flucke UE; van Herpen CML
    Int J Cancer; 2018 Aug; 143(4):758-766. PubMed ID: 29492965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.
    Saintigny P; Mitani Y; Pytynia KB; Ferrarotto R; Roberts DB; Weber RS; Kies MS; Maity SN; Lin SH; El-Naggar AK
    Cancer; 2018 Sep; 124(18):3693-3705. PubMed ID: 30289966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation.
    Ettl T; Schwarz-Furlan S; Haubner F; Müller S; Zenk J; Gosau M; Reichert TE; Zeitler K
    Oral Oncol; 2012 Sep; 48(9):822-30. PubMed ID: 22445095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations.
    Wang K; Russell JS; McDermott JD; Elvin JA; Khaira D; Johnson A; Jennings TA; Ali SM; Murray M; Marshall C; Oldham DS; Washburn D; Wong SJ; Chmielecki J; Yelensky R; Lipson D; Miller VA; Stephens PJ; Serracino HS; Ross JS; Bowles DW
    Clin Cancer Res; 2016 Dec; 22(24):6061-6068. PubMed ID: 27334835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular and biomarker analyses of salivary duct carcinomas: comparison with mammary duct carcinoma.
    Hoang MP; Callender DL; Sola Gallego JJ; Huang Z; Sneige N; Luna MA; Batsakis JG; El-Naggar AK
    Int J Oncol; 2001 Oct; 19(4):865-71. PubMed ID: 11562768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature.
    Fan CY; Wang J; Barnes EL
    Am J Surg Pathol; 2000 Apr; 24(4):579-86. PubMed ID: 10757407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients.
    van Boxtel W; Verhaegh GW; van Engen-van Grunsven IA; van Strijp D; Kroeze LI; Ligtenberg MJ; van Zon HB; Hendriksen Y; Keizer D; van de Stolpe A; Schalken JA; van Herpen CM
    Int J Cancer; 2020 Jun; 146(11):3196-3206. PubMed ID: 31745978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The molecular landscape and microenvironment of salivary duct carcinoma reveal new therapeutic opportunities.
    Alame M; Cornillot E; Cacheux V; Tosato G; Four M; De Oliveira L; Gofflot S; Delvenne P; Turtoi E; Cabello-Aguilar S; Nishiyama M; Turtoi A; Costes-Martineau V; Colinge J
    Theranostics; 2020; 10(10):4383-4394. PubMed ID: 32292502
    [No Abstract]   [Full Text] [Related]  

  • 35. Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma.
    Fan CY; Melhem MF; Hosal AS; Grandis JR; Barnes EL
    Arch Otolaryngol Head Neck Surg; 2001 Sep; 127(9):1075-9. PubMed ID: 11556855
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular characterization of apocrine salivary duct carcinoma.
    Chiosea SI; Williams L; Griffith CC; Thompson LD; Weinreb I; Bauman JE; Luvison A; Roy S; Seethala RR; Nikiforova MN
    Am J Surg Pathol; 2015 Jun; 39(6):744-52. PubMed ID: 25723113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical Reactivity of Prostate-Specific Markers for Salivary Duct Carcinoma.
    Takada N; Nishida H; Oyama Y; Kusaba T; Kadowaki H; Arakane M; Wada J; Urabe S; Daa T
    Pathobiology; 2020; 87(1):30-36. PubMed ID: 31865345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers.
    Guiu S; Mollevi C; Charon-Barra C; Boissière F; Crapez E; Chartron E; Lamy PJ; Gutowski M; Bourgier C; Romieu G; Simony-Lafontaine J; Jacot W
    Br J Cancer; 2018 Jul; 119(1):76-79. PubMed ID: 29880907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Salivary duct carcinomas comprise phenotypically and genotypically diverse high grade neoplasms].
    Hungermann D; Korsching E; Bürger H; Röser K; Löning T; Herbst H
    Verh Dtsch Ges Pathol; 2006; 90():168-76. PubMed ID: 17867594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salivary duct carcinoma: new developments--morphological variants including pure in situ high grade lesions; proposed molecular classification.
    Simpson RH
    Head Neck Pathol; 2013 Jul; 7 Suppl 1(Suppl 1):S48-58. PubMed ID: 23821208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.